Plain-English translation of NCT06934252 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called , given as injections under the skin, to see if it is safe and works for people with moderate-to-severe atopic dermatitis (a chronic condition that causes severe itching and inflamed skin). The trial starts by giving the medication to healthy volunteers in gradually increasing doses to make sure it is safe, and then tests it in patients who actually have the skin condition. Researchers will watch carefully for any side effects and measure how well the treatment works.
Atopic dermatitis can be very uncomfortable and hard to treat with current options. This trial is exploring whether this new medication could offer another treatment choice for people whose skin condition is not controlled well enough by existing therapies.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive injections of either the new medication or a placebo (a dummy injection with no active ingredient) every 4 weeks for 8 to 12 weeks, depending on which part of the study you join. Healthy volunteers will have follow-up visits for 10 to 12 weeks after their last injection; patients with skin disease may have the option to cross over and receive the opposite treatment (placebo or medication) in a second phase. Throughout the study, you will have blood tests, physical exams, and assessments of how your skin is doing.
AI-generated summary from trial data · Jun 21, 2026 · Not medical advice
Australia